Table 1.
Characteristics of patient population in phase II portion of trial (N = 55)
| Characteristics | Stratum A (N = 33) ER and/or PR-positive, non- inflammatory carcinoma | Stratum B (N = 22) inflammatory carcinoma |
|---|---|---|
| Median age (range) | 50.4 years (33–76) | 54.5 years (34–77) |
| ECOG PS | ||
| 0 | 28 (85 %) | 19 (87 %) |
| 1 | 5 (15 %) | 3 (13 %) |
| Clinical stage | ||
| Stage IIA–IIIA | 31 (94 %) | 0 |
| Stage IIIB non-inflammatory | 2(6%) | 0 |
| Stage IIIB inflammatory | 0 | 16 (73 %) |
| Stage IIIC inflammatory | 0 | 6 (27 %) |
| ER/PR expressiona | ||
| ER+/PR+ | 26 (79 %) | 8 (36 %) |
| ER+/PR– | 7 (21 %) | 4 (18 %) |
| ER–/PR+ | 0 | 1 (5 %) |
| ER–/PR– | 0 | 9 (41 %) |
| Menopausal status | ||
| Pre/peri-menopausal | 18 (55 %) | 8 (36 %) |
| Postmenopausal | 15 (45 %) | 14 (64 %) |
a
ER/PR expression coded as per ASCO-CAP guidelines